scholarly journals Cardiovascular prevention in peri- and postmenopausal women

2011 ◽  
Vol 10 (3) ◽  
pp. 123-130
Author(s):  
N. A. Voychenko ◽  
I. V. Kuznetsova ◽  
V. B. Mychka ◽  
M. Yu. Kirillova ◽  
S. N. Tolstov
Keyword(s):  
Quality Of Life ◽  
Cardiovascular Disease ◽  
Hormone Replacement Therapy ◽  
Postmenopausal Women ◽  
Lower Risk ◽  
Ovarian Function ◽  
Hormone Replacement ◽  
Cardiovascular Prevention ◽  
Cvd Risk

The adverse consequences of estrogen deficiency in postmenopause include cardiovascular disease (CVD), which affects not only women’s quality of life, but also their life expectancy. Before premenopause, women have significantly lower risk of arterial hypertension than men of the same age. However, in people aged over 50, AH is more prevalent among women. Currently, most experts regard hormone replacement therapy (HRT) in peri- and postmenopausal women as pathogenetic, since it facilitates the adaptation of the female organism to the new metabolic state, with reduced ovarian function. Drospirenone, as a part of HRT, reduces CVD risk in postmenopausal women with climacteric disturbances.

Hormone replacement therapy and the endometrium

2009 ◽  
Vol 15 (3) ◽  
pp. 134-138 ◽  
Author(s):  
S Daayana ◽  
C M Holland
Keyword(s):  
Quality Of Life ◽  
Hormone Replacement Therapy ◽  
Replacement Therapy ◽  
Postmenopausal Women ◽  
Hormone Replacement ◽  
Symptom Relief ◽  
Careful Consideration ◽  
Age Group ◽  
Individual Woman

The life-expectancy for women has increased significantly in the 20th century, although the time of onset of menopause has not. Almost a third of a woman's life is now postmenopausal and therefore many postmenopausal women consider using hormone replacement therapy (HRT) to improve their quality of life. Most cases of endometrial carcinoma arise in postmenopausal women and this raises concern among patients and clinicians with regard to the safety of HRT in this age group. Whenever the use of HRT is considered, a careful consideration of the actual benefit in terms of symptom relief and quality of life must be balanced against the risks for each individual woman. This review discusses the effects of HRT on the endometrium and the evidence regarding HRT use and risk of endometrial cancer.

Continuous combined hormone replacement therapy relieves climacteric symptoms and improves health-related quality of life in early postmenopausal women

2007 ◽  
Vol 13 (3) ◽  
pp. 116-123 ◽  
Author(s):  
Joan Pitkin ◽  
Vera Petrovna Smetnik ◽  
Péter Vadász ◽  
Mika Mustonen ◽  
Kaisa Salminen ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Hormone Replacement Therapy ◽  
Postmenopausal Women ◽  
Hormone Replacement ◽  
Health Related Quality ◽  
Climacteric Symptoms ◽  
Early Postmenopausal Women ◽  
Related Quality ◽  
Health Related

Objective. Hormone replacement therapy (HRT) relieves menopausal symptoms but its effect on health related quality of life (HRQoL) is uncertain. The aim of this study was to assess the effect of three dose regimens of continuous combined HRT, consisting of estradiol valerate (E2V) and medroxyprogesterone acetate (MPA) on HRQoL in early postmenopausal women (last menstrual period 1–3 years before study entry). Study design. This was a 52-week, randomized, double-blind, multinational study comparing E2V (1 mg or 2 mg) plus MPA (2.5 mg or 5 mg) in different dose combinations. The intention-to-treat population comprised 459 women (average age 51.5 years). Main outcome measures. HRQoL was assessed by the Women's Health Questionnaire (WHQ), the 15D Questionnaire and a visual analogue scale (VAS). Results. There were improvements on eight of the nine domains of the WHQ with all dose regimens during the first 12 weeks ( P<0.0001) and an improvement in the remaining domain (menstrual symptoms) with the lower-dose regimens ( P<0.05). These initial improvements in HRQoL were then maintained or augmented over the remainder of the study ( P<0.0001 for change from baseline at 52 weeks for all domains and dose regimens). Mean 15D total score had improved meaningfully and significantly by 12 weeks ( P<0.0001 versus baseline) in all treatment groups and this improvement was maintained thereafter. This improvement in 15D total score was most marked among previous non-users of HRT ( P<0.05 versus previous users). VAS scores recorded significant ( P<0.05) reductions in hot flushes, sweating and sleep disturbances in all groups after week 1 and highly significant ( P<0.0001) relief of all climacteric symptoms at week 52. Conclusion. Continuous combined HRT was associated with pronounced improvement of vasomotor symptoms and HRQoL in this population of early postmenopausal women.

Sign in / Sign up

Export Citation Format

Share Document